Use of radiopharmaceuticals and intraoperative radiation probe for delivery of medicinal treatments

• US 6,602,488 B1
• Filed: 03/03/2000
• Issued: 08/05/2003
• Est. Priority Date: 03/03/2000
• Status: Expired due to Term

• Current Assignee: Intra Medical Imaging, LLC
• Original Assignee: IntraMedical Imaging, LLC
• Inventors: Daghighian, Farhad
• Primary Examiner(s): JONES, DAMERON LEVEST
• Application Number:
  US09/518,457
• Time in Patent Office: 1,250 Days
• Field of Search: 424/9.1, 424/9.3, 424/1.11, 424/9.4, 424/9.5, 424/9.6, 424/9.7
• US Class Current: 424/9.3
• CPC Class Codes: A61B 2034/2051 Electromagnetic tracking systems
• CPC Class Codes: A61K 49/18 characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• CPC Class Codes: A61K 51/1282 Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
• CPC Class Codes: G01T 1/161 Applications in the field of nuclear medicine, e.g. in vivo counting apparatus for radiation diagnosis A61B6/00

Abstract

Claims

1. A method of genetically altering diseased living tissue in a human body comprising:

a) delivering a radionuclide labeled, tissue specific material to a patient,

b) allowing the radionuclide labeled, tissue specific material to circulate through the patient'"'"'s body until said material concentrates at intended diseased target tissue, resulting in radiolabeled diseased tissue,

c) locating the situs of the radiolabeled diseased tissue,

d) placing a nuclear probe having treatment delivery capabilities incorporated therewith adjacent the situs of the radio-labeled diseased tissue,

e) targeting the radio-labeled diseased tissue using the nuclear probe, and

f) delivering genetic material prepared for treatment purposes directly to the targeted radio-labeled diseased tissue while targeted by the probe to assure delivery of the genetic material to radiolabeled diseased tissue to be altered to modify the diseased tissue.

2. The method of claim 1 further comprising, between step b) and step c), placing the patient within the field of an MRI diagnostic device with the radio-labeled diseased tissue located within an area for diagnosis using the MRI device.

3. The method of claim 1 wherein the nuclear probe comprises multiple detectors, an array of detectors or a continuous film of detectors, said nuclear probe capable of providing an image of radiation distribution across the radiolabeled diseased tissue.

4. A method of altering diseased living tissue in a human body comprising:

a) delivering a radionuclide labeled, tissue specific material to a patient,

b) allowing the radionuclide labeled, tissue specific material to circulate through the patient'"'"'s body until said material concentrates at intended diseased target tissue, resulting in radiolabeled diseased tissue,

c) locating the situs of the radiolabeled diseased tissue,

d) placing a nuclear probe having treatment delivery capabilities incorporated therewith adjacent the situs of the radio-labeled diseased tissue,

e) targeting the radio-labeled diseased tissue using the nuclear probe, and

f) delivering cells, biological vectors or carriers of genetic material prepared for treatment purposes directly to the targeted radio-labeled diseased tissue while targeted by the probe to assure delivery of the cells, biological vectors or carriers of genetic material to the radiolabeled diseased tissue to be altered to modify the diseased tissue.

5. The method of claim 4 further comprising, between step b) and step c), placing the patient within the field of an MRI diagnostic device with the radio-labeled diseased tissue located within an area for diagnosis using the MRI device.

6. The method of claim 4 wherein the nuclear probe comprises multiple detectors, and an array of detectors or a continuous film of detectors, said nuclear probe capable of providing an image of radiation distribution across the radiolabeled diseased tissue.